Royalty Pharma expands investment strategy in biotech drug makers

Royalty Pharma is expanding its investment strategy to provide capital to drug makers and developers in the biotech sector. Royalty Pharma does not operate as a pharmaceutical or biotech company itself; instead, it provides cash to these companies to advance research and receives a royalty on the resulting drug sales. This model allows Royalty Pharma to diversify its portfolio across many drugs, collecting small royalties that accumulate.

The biotech sector is often described as high-risk, high-reward, as many companies rely on a single drug for market viability. Royalty Pharma's approach mitigates this risk by investing in a diversified portfolio. The company's model generates revenue through royalties rather than through the direct sale of its own products.